SOURCE-LINKED STUDY SUMMARY
Safety and Efficacy of Dietary Agmatine Sulfate in Lumbar Disc-associated Radiculopathy. An Open-label, Dose-escalating Study Followed by a Randomized, Double-blind, Placebo-controlled Trial.
Abstract summarizedQuality not appraised
- What was studied
- An open-label dose-escalation study assessed agmatine safety, followed by a randomized double-blind placebo-controlled trial for lumbar disc-associated radiculopathy.
- Who / model studied
- The randomized trial enrolled 51 participants to agmatine and 48 to placebo, but analyzed only 31 and 30, respectively.
- Studied dose & schedule
- The randomized phase tested oral agmatine sulfate 2.670 g/day versus placebo for 14 days.
- What the study found
- Pain improved 26.7% with agmatine versus 6.0% with placebo; quality-of-life scores improved 70.8% versus 20.0%. No treatment-related adverse events were reported in the randomized phase.
- Limitations & context
- The analyzed randomized sample was much smaller than the enrolled sample, treatment lasted 14 days, and the results concern radiculopathy—not exercise performance or muscle effects.
Read summary source ↗ · Prepared 10/6/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1111/j.1526-4637.2010.00808.x